Key result
Short-acting beta-blockers control heart rate in septic shock but show inconsistent mortality effects.
Why the study?
Tachycardia in sepsis is associated with poor outcomes, but its impact varies with tissue perfusion and left ventricular ejection fraction, creating uncertainty about beta-blocker use.
Do short-acting beta-blockers (esmolol or landiolol) effectively control heart rate and improve clinical outcomes (such as organ function and mortality) in tachycardic patients with septic shock?
Do short-acting beta-blockers (esmolol or landiolol) effectively control heart rate and improve clinical outcomes (such as organ function and mortality) in tachycardic patients with septic shock?
Systematic administration of short-acting beta-blockers in tachycardic septic shock patients remains debatable due to conflicting mortality results and increased vasopressor requirements, necessitating prior echocardiographic evaluation and advanced hemodynamic monitoring to select patients with hyperkinetic hearts and preserved systolic function.
Answers are grounded in this paper and cite their sources.
Conflicting mortality data advise against routine use of short-acting beta-blockers in septic shock; leaves open whether they improve survival in definitive trials.
Septic shock is associated with severe vasoplegia, increased permeability, maldistribution of regional blood flows, and microvascular alterations. Hemodynamic management includes fluid and vasopressor agents and, in selected cases, inotropic agents. However, several patients remain tachycardic after initial resuscitation. Tachycardia is frequently observed in sepsis and is associated with a poor outcome. [ 1 ] Given the negative impact of tachycardia, the use of short-acting beta-blockers was proposed. [ 2 ] Of note, tachycardia was suggested to be protective in patients with increased lactate levels whereas opposite effects were observed in patients with normal lactate levels. [ 3 ] The impact of tachycardia should hence not be evaluated without looking at tissue perfusion. In addition, patients in septic shock with elevated left ventricular (LV) ejection fraction (EF) at echocardiography present an increased risk of death. In a retrospective single-center study including 1014 patients, an elevation in LVEF was found to be independently correlated with mortality (odds ratio = 3.90 [2.09–7.40]). [ 4 ] In another cohort of patients with sepsis and septic shock, the relationship between LVEF and mortality showed a U -shaped pattern, with severely impaired ( < 25%) and elevated ( ≥ 70%) EF, both being independently associated with an increased risk of death. [ 5 ] In tachycardic hyperkinetic hearts, beta-blockers
No takes yet. Share an insight, caveat, or question.
Backer et al. (2024) conducted a review in Septic shock with tachycardia. Short-acting beta-blockers (esmolol, landiolol) vs. Usual care or placebo was evaluated on Heart rate control (80-94 bpm) and 28-day mortality across reviewed RCTs. Short-acting beta-blockers effectively control heart rate in septic shock, but show conflicting 28-day mortality results across trials.
Synapse has enriched 10 related papers. Consider them for comparative context: